21:22 , Jan 18, 2019 |  BioCentury  |  Politics, Policy & Law

Pharma falling off budget cliff

Three strong arms are lining up in Washington to take turns whacking the biopharma piñata. Divisions within the industry, a lack of new ideas, and resistance to change are making a bad situation worse for...
17:38 , Jan 11, 2019 |  BC Week In Review  |  Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) said on Jan. 7 it reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in...
20:46 , Jan 9, 2019 |  BC Extra  |  Politics & Policy

House bill would push Part D price negotiations

A bipartisan bill introduced in Congress Tuesday aims to force the Trump administration's hand on Medicare Part D price negotiations, and would require HHS to bargain directly with drugmakers. HHS Secretary Alex Azar has previously...
15:12 , Jan 7, 2019 |  BC Extra  |  Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) has reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in the wake of the...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
23:04 , Dec 20, 2018 |  BC Innovations  |  Finance

Third Rock keeps its options open

Third Rock Ventures is cementing its strategy to create newcos that can succeed as stand-alone companies. The VC has ditched the build-to-buy model in favor of one that gives a pharma broad options to multiple...
03:31 , Dec 7, 2018 |  BC Innovations  |  Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
21:11 , Dec 6, 2018 |  BC Extra  |  Politics & Policy

FDA smoothing the path for class-wide cancer companion diagnostics

FDA Thursday announced the availability of draft guidance that is intended to make it easier for cancer companion diagnostics to be approved for a class of drugs, rather than only for a specific drug. FDA...
15:41 , Dec 6, 2018 |  BC Extra  |  Politics & Policy

Newly named Azar adviser O'Brien defends pricing index

John O'Brien is taking over as the point person on the Trump administration's drug pricing strategy as its plans to tie Medicare Part B drug prices to an international reference pricing scheme have come under...
22:28 , Nov 20, 2018 |  BC Extra  |  Politics & Policy

FDA planning class-wide cancer companion diagnostic guidance

FDA plans to release guidance soon that will make it easier to get a cancer companion diagnostic approved for use with an entire class of drugs, FDA Commissioner Scott Gottlieb told BioCentury. Class-wide labeling would...